SuperGen Announces Identification of new Class of Etk/Bmx Kinase Inhibitors at the AACR 100th Annual Meeting 2009
News Apr 23, 2009
SuperGen Inc. has announced as part of a series of presentations at the 100th Annual Meeting of the American Association for Cancer Research (AACR), that it has identified a new class of small molecules which successfully inhibit Etk/Bmx kinase in preclinical cancer models.
Entitled, “Targeting Etk/Bmx kinase with small molecule inhibitors,” the poster highlights data indicating that SuperGen lead compounds in this class inhibit the autophosphorylation of Etk, the activation of STAT3 downstream of EGF stimulation, and inhibit the colony formation of prostate and liver cancer cells lines in soft agar.
“SuperGen is committed to bringing first in class drugs into the clinic against cancer drug targets, and Etk/Bmx represents another one of these targets,” said Dr. David Bearss, SuperGen’s Chief Scientific Officer. “We are excited about selecting a clinical candidate for this program and think this program signifies another example of what our company and drug discovery technology can accomplish.”
Algorithm Unearths Over 1000 Antibiotic Proteins in a Few HoursNews
The algorithm identified 10 times more peptide variations than all previous discoveries combined, aiding the hunt for new antibiotics.READ MORE
Protein That Helps Keep Breast Cancer Dormant IdentifiedNews
A protein kinase that stops breast cancer cells growing and spreading has been outlined in new research.READ MORE
Barrier to Liquid Biopsies Overcome with Blood Stabilization TechniqueNews
A new technique that prolongs the lifespan of blood samples could be a breakthrough for liquid biopsy assays.READ MORE